Flonase highlights GSK's ambitions in OTC

12 May 2015 - Deborah Wilkes

Archived

GlaxoSmithKline said sales of Flonase Allergy Relief had reached £65 million (US$101 million) in the first quarter of 2015, following the recent switch to OTC status in the US. The company noted that switching medicines from prescription to OTC status would be "an important component of growth" for its global Consumer Healthcare joint venture with Novartis.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: